Skip to content

Graviton Bioscience

ROCK2 inhibitors for fibrotic and autoimmune diseases

Raised to date

$5M

of $75M offered across 1 Form D filing

Still open
$70M
Investors
2
Last filed
Nov 13, 2026

About

Graviton Bioscience is a New York clinical-stage biotechnology company developing selective ROCK2 inhibitors for fibrotic, autoimmune and CNS diseases. Its lead candidate GV101, an oral ROCK2 inhibitor, received FDA Fast Track designation for Friedreich's ataxia in November 2026 and is entering a Phase 2 study. The company has partnerships with Ovid Therapeutics, Sino Biopharmaceutical and Sanofi, and lists eight drug candidates in development.

A portfolio of selective ROCK2 inhibitors across fibrotic, autoimmune and CNS indications, backed by partnerships with Sanofi, Ovid and Sino Biopharmaceutical.

Funding

  • EquityFiled Nov 13, 2026Form D
    $5M/ $75M

Product

GV101

Clinical-stage small molecule therapeutic

Oral, potent and selective ROCK2 inhibitor in clinical development for Friedreich's ataxia, which has also been studied for weight loss in obesity.

  • Oral selective ROCK2 inhibitor
  • FDA Fast Track designation for Friedreich's ataxia
  • IND cleared, Phase 2 dose-ranging study starting

Built for

Patients with fibrotic, autoimmune and CNS diseases, and pharma partners

People on file